Wave of AI Imaging Tools Receive FDA Clearance

- The FDA is actively developing a regulatory framework for AI/ML-based medical devices, releasing an action plan in 2021 and subsequent guidance on good machine learning practices and transparency. This framework includes pathways like 510(k) clearance and a Predetermined Change Control Plan to manage algorithm updates without requiring new approvals for every modification. - Zebra Medical Vision's HealthMammo tool, which flags suspicious mammograms for prioritized review, was the company's sixth FDA 510(k) clearance and its first in oncology. This made Zebra the first AI startup to gain clearances across three different imaging modalities: CT, X-ray, and mammography. - Positrigo’s NeuroLF PET system is a compact, dedicated brain imaging device that allows patients to be scanned while seated, a design intended to facilitate point-of-care functional imaging for neurological conditions. This clearance comes as new Alzheimer's therapies, which can be monitored with PET imaging, are also receiving FDA approval. - The latest version of Sonio Detect for fetal ultrasound demonstrates high sensitivity for detecting key fetal views (91.4% for T1 and 93.7% for T2/T3) and can automate over 60% of exam protocols, potentially saving up to 10 minutes on complex exams. The software is designed to integrate with various ultrasound manufacturers' systems. - CureMetrix's cmAngio received its initial 510(k) clearance for Hologic systems in October 2023 and later expanded its clearance to include GE HealthCare mammography platforms. This allows the AI to identify breast arterial calcification, an incidental finding, on screening mammograms from a wider range of equipment. - The broader trend in diagnostic imaging is a shift toward outpatient settings, driven by reimbursement changes and the pursuit of more convenient, cost-effective care. Freestanding imaging centers are the fastest-growing segment, with a projected compound annual growth rate (CAGR) of 7.11%. - Persistent radiologist shortages and burnout, exacerbated by increasing imaging volume and complexity, are key drivers for the adoption of AI tools to improve workflow efficiency and support clinical decisions. Projections indicate a potential shortage of up to 42,000 radiologists in the U.S. by 2033. - Reimbursement for AI in radiology is evolving, with pathways including New Technology Add-on Payments (NTAPs) for inpatient settings and the assignment of Category III CPT codes to track the usage of emerging technologies. However, the lack of consistent reimbursement remains a significant barrier to widespread adoption.